Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients, both in terms of innovative treatments, but also via use of innovative prevention, […]
Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of […]
EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient organisations and the biopharmaceutical industry. […]
EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for […]
The development of therapies (OMPs) for rare diseases comes with distinct challenges, including patient recruitment, setting meaningful clinical endpoints, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy.
On 15th March, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels, with the aim of setting the vision for Europe's global innovation, competitiveness, and sustainability on biomanufacturing, while raising awareness among policy-makers.
Biomanufacturing within healthcare represents an advance in therapeutic capabilities, as ground-breaking research translates into increased diseases that can be targeted, either for the first time or with greater efficacy, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems.
EuropaBio, and AseBio, the Spanish Association of Biotechnology Companies, with the support of Merck, will host a summer reception to mark the beginning of the Spanish Council […]
In April 2023, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem.
EuropaBio is pleased to announce that this year's edition of EFIB, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title 'Industrial biotechnology for a sustainable and resilient global […]
Hybrid Event | Invitation Only EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient […]
Industrial biotechnology for a sustainable and resilient global Europe As the EU looks ahead to the European elections in 2024, with a new EU Commission mandate […]
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
